[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363645-105":59,"doc-detail-363645-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","transcriptionally-informed-nucleosome-profiling-of-circulating-cell-free-dna-predicts-breast-cancer-recurrence-research-article","Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence - Research Article","","Cell-free DNA (cfDNA) provides a minimally invasive way to track genomic and epigenetic changes during breast cancer progression. Targeted sequencing of 26 transcriptionally regulated loci was used to analyze blood-derived cfDNA from 150 samples, including primary and recurrent cases. Recurrent samples showed more variants in coding and noncoding regions, shorter fragment lengths, and distinct nucleosome-associated signals that separated recurrence with high accuracy. Machine learning integrating cfDNA features predicted relapse and supports sensitive, transcription-focused liquid biopsy detection.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/transcriptionally-informed-nucleosome-profiling-of-circulating-cell-free-dna-predicts-breast-cancer-recurrence-research-article/363645/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/transcriptionally-informed-nucleosome-profiling-of-circulating-cell-free-dna-predicts-breast-cancer-recurrence-research-article/363645.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does the study use cfDNA to study breast cancer progression?","Question",{"text":113,"@type":114},"It analyzes blood-derived cfDNA to capture genomic and epigenetic dynamics associated with cancer progression and therapy resistance, using targeted sequencing and fragmentation-related measures.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What key cfDNA differences are observed between primary and recurrent samples?",{"text":118,"@type":114},"Recurrent samples show increased genomic variant counts in coding and noncoding regions, shorter cfDNA fragment lengths, and variable fragmentation profiles with locus-specific amplification and reductions.",{"name":120,"@type":111,"acceptedAnswer":121},"How are nucleosome-derived signals applied to predict recurrence?",{"text":122,"@type":114},"The study derives nucleosome occupancy–based scores from loci including RERE and SYNPO2, then uses these cfDNA features with a machine-learning approach to accurately predict breast cancer relapse.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363645,1790334221,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-26-0263](https://doi.org/10.1158/2767-9764.CRC-26-0263)  OPEN ACCESS  \nTranscriptionally Informed Nucleosome   \nProfiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence  \nSugiko Watanabe1, Kan Etoh1,2, Jun Mitsui3, Yuta Suzuki4, Yutaka Yamamoto5, and Mitsuyoshi Nakao1  \n􀀶  \nABSTRACT  \nCell-free DNA (cfDNA) offers a minimally invasive approach to capture genomic and epigenetic dynamics during cancer progression. We performed targeted sequencing of 26 gene loci transcriptionally regulated during the acquisition of therapy resistance in breast cancer and analyzed blood-derived cfDNA from 150 breast cancer samples (105 primary and 45 recurrent) . Recurrent samples exhibited increased genomic variant counts in both coding and noncoding regions, accompanied by shorter cfDNA fragment lengths. Furthermore, cfDNA fragmentation profiles were variable in recurrent samples, with frequently amplified loci such as ERBB2 and concurrent reductions at loci, including RERE and SYNPO2 . Notably, nucleosome occupancy–derived scores from RERE and SYNPO2 distinguished recurrent from primary cancer with high accuracy (area under the curve ¼ 0.826) . Using a machine-  \nlearning approach, integration of these cfDNA features accurately predicted breast cancer relapse. Collectively, these findings demonstrate that cfDNA-based profiling focused on transcriptional alterations provides a sensitive strategy for detecting breast cancer recurrence.  \nSignificance: cfDNA-based (epi)genomic profiling captures transcriptionally regulated chromatin and nucleosome remodeling during the acquisition of therapy resistance and relapse, enabling minimally invasive, mechanistically informed detection of breast cancer recurrence. Targeting transcriptionally relevant genomic loci provide clinically actionable biomarkers to monitor therapy resistance and guide precision treatment decisions in real time.  \nIntroduction  \nBreast cancer is one of the most common cancers among women worldwide ( 1) . Based on molecular features, including the expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), breast cancers are classified into distinct clinical subtypes. The majority of patients with early-stage breast cancer can be cured with surgery  \n1Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan. 2Department of Molecular Cell Biology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 3Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 4Department of Computer Science, Graduate School of Information Science and Technology, The University of Tokyo, Tokyo, Japan. 5Department of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Japan.  \nS. Watanabe and K. Etoh contributed equally to this article.  \nCorresponding Authors: Sugiko Watanabe, Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1, Honjo, Chuo-ku, Kumamoto 860-0811, Japan. E-mail: [sugikow@kumamoto-u.ac.jp](sugikow@kumamoto-u.ac.jp); and Mitsuyoshi Nakao, [mnakao@gpo.kumamoto-u.ac.jp](mnakao@gpo.kumamoto-u.ac.jp)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-26-0263  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \nand radiotherapy in combination with subtype-specific chemotherapy (2) . However, a subset of patients develops disease recurrence and therapy resistance, a risk that increases further in advanced stages. Although genomic alterations, such as mutations in ESR1 or PIK3CA, are well-established mechanisms underlying therapy resistance (3–5), nongenetic features, including enhancer reprogramming","cbCaifJX3j97LBBP","https://ap.wps.com/l/cbCaifJX3j97LBBP","pdf",7600060,"English","# Abstract\n## Significance\n# Introduction\n## Breast cancer subtypes and therapy resistance\n## Study rationale for cfDNA liquid biopsy","[{\"question\":\"How does the study use cfDNA to study breast cancer progression?\",\"answer\":\"It analyzes blood-derived cfDNA to capture genomic and epigenetic dynamics associated with cancer progression and therapy resistance, using targeted sequencing and fragmentation-related measures.\"},{\"question\":\"What key cfDNA differences are observed between primary and recurrent samples?\",\"answer\":\"Recurrent samples show increased genomic variant counts in coding and noncoding regions, shorter cfDNA fragment lengths, and variable fragmentation profiles with locus-specific amplification and reductions.\"},{\"question\":\"How are nucleosome-derived signals applied to predict recurrence?\",\"answer\":\"The study derives nucleosome occupancy–based scores from loci including RERE and SYNPO2, then uses these cfDNA features with a machine-learning approach to accurately predict breast cancer relapse.\"}]","Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence - Research Article | PDF",1790152336,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29392da4d2a3a1bbe49529972732f685.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60f90d37ca5cf4a9d464436793949f5c.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/324ad1a8816e56383e7fda950c5a4337.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f93f1db7e54d25d2cef68126735a5e59.webp",980,1259]